Sudarshan Pharma Industries Limited (BOM:543828)
35.60
-0.71 (-1.96%)
At close: Aug 17, 2026
BOM:543828 Revenue
Sudarshan Pharma Industries had revenue of 1.76B INR in the quarter ending June 30, 2026, with 20.91% growth. This brings the company's revenue in the last twelve months to 7.32B, up 32.86% year-over-year. In the fiscal year ending March 31, 2026, Sudarshan Pharma Industries had annual revenue of 7.03B with 39.21% growth.
Revenue (ttm)
7.32B
Revenue Growth
+32.86%
P/S Ratio
1.19
Revenue / Employee
122.04M
Employees
60
Market Cap
8.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 7.03B | 1.98B | 39.21% |
| Mar 31, 2025 | 5.05B | 415.07M | 8.95% |
| Mar 31, 2024 | 4.64B | 22.10M | 0.48% |
| Mar 31, 2023 | 4.61B | 1.04B | 29.19% |
| Mar 31, 2022 | 3.57B | 1.64B | 84.52% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.79B |
| Lincoln Pharmaceuticals | 7.03B |
| Kopran | 7.00B |
| Wanbury | 6.53B |
| Fermenta Biotech | 5.11B |
| Syncom Formulations (India) | 4.89B |
| Hexagon Nutrition | 4.15B |
| ZIM Laboratories | 3.97B |
Sudarshan Pharma Industries News
- 3 days ago - Sudarshan Pharma Industries Slides: Investor presentation - Filings
- 5 days ago - Sudarshan Pharma Industries Quarterly report: Q1 2027 - Filings
- 3 months ago - Sudarshan Pharma Industries Quarterly report: Q4 2026 - Filings
- 7 months ago - Sudarshan Pharma Industries Quarterly report: Q3 2026 - Filings
- 10 months ago - Sudarshan Pharma Industries Quarterly report: Q2 2026 - Filings